Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
Federal Trade Commission
McKinsey
Queensland Health
Boehringer Ingelheim

Generated: May 20, 2019

DrugPatentWatch Database Preview

FARYDAK Drug Profile

« Back to Dashboard

When do Farydak patents expire, and when can generic versions of Farydak launch?

Farydak is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and eleven patent family members in forty-seven countries.

The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the panobinostat lactate profile page.

Summary for FARYDAK
Drug patent expirations by year for FARYDAK
Generic Entry Opportunity Date for FARYDAK
Generic Entry Date for FARYDAK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for FARYDAK
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
(E)-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enehydroxamic acid
(E)-N-Hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide
(E)-N-hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide
(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE
(E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indole-3-yl)ethyl]amino]methyl]phenyl]acrylamide
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
139304-EP2270008A1
139304-EP2292617A1
2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)-, (2E)-
2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)-
404950-80-7
4CA-0964
9647FM7Y3Z
A25218
A8178
AB0007883
ABP000143
AC-28652
AC1OCFY8
ACN-025765
AJ-80437
AK-77283
AKOS005146046
AM808102
AOB87727
AS-17046
AX8223959
BC203264
BCP01816
BCP9000844
BCPP000187
BDBM198124
BDBM29589
BR-77283
BRD-K02130563-001-07-2
CCG-208762
CHEBI:85990
CHEBI:93774
CHEMBL483254
CS-0267
D10319
DB-025426
DB06603
DTXSID40193506
EX-8456
EX-A169
Faridak
Farydak (TN)
FPOHNWQLNRZRFC-ZHACJKMWSA-N
FT-0083488
GTPL7489
HY-10224
J-523585
KB-59423
LBH 589
LBH-589
LBH-589/Panobinostat /LBH589
LBH-589B
LBH58,9NVP-LBH589,Panobinostat
LBH589
LBH589 - Panobinostat
MLS006011216
MolPort-005-933-338
N-hydroxy-3 -[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
N-Hydroxy-3-[4-[2-(2-methyl-1H-indol-3-yl)ethylaminomethyl]phenyl]-2(E)-propenamide
NCGC00263117-07
NVP-LBH 589; Panobinostat
NVP-LBH-589
NVP-LBH589
Panobinostat
Panobinostat (LBH589)
Panobinostat (USAN/INN)
Panobinostat [USAN:INN]
Panobinostat;(E)-N-hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide
Panobinostat(LBH589)
PubChem19147
QC-10419
RL03555
RT-014934
s1030
SB16464
SC-85907
SCHEMBL164801
SCHEMBL183197
SMR004702978
ST2402529
SW219369-1
UNII-9647FM7Y3Z
W-5406
W6096
ZINC22010649

US Patents and Regulatory Information for FARYDAK

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp FARYDAK panobinostat lactate CAPSULE;ORAL 205353-001 Feb 23, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp FARYDAK panobinostat lactate CAPSULE;ORAL 205353-003 Feb 23, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp FARYDAK panobinostat lactate CAPSULE;ORAL 205353-001 Feb 23, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp FARYDAK panobinostat lactate CAPSULE;ORAL 205353-001 Feb 23, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp FARYDAK panobinostat lactate CAPSULE;ORAL 205353-002 Feb 23, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for FARYDAK

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1318980 1590070-7 Sweden ➤ Sign Up PRODUCT NAME: PANOBINOSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALTTHEREOF; REG. NO/DATE: EU/1/15/1023 20150901
1318980 300778 Netherlands ➤ Sign Up PRODUCT NAME: PANOBINOSTAT, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/15/1023 20150901
1912640 PA2016003,C1912640 Lithuania ➤ Sign Up PRODUCT NAME: PANOBINOSTATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/1023 20120828
1318980 72/2015 Austria ➤ Sign Up PRODUCT NAME: PANOBINOSTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1023 (MITTEILUNG) 20150901
1318980 15C0086 France ➤ Sign Up PRODUCT NAME: PANOBINOSTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/1023 20150901
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
UBS
Covington
Baxter
Fish and Richardson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.